The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
India’s pharmaceutical sector stands at a pivotal inflection point
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Subscribe To Our Newsletter & Stay Updated
